20.40 0.00 (0.00%)
After hours: 4:53PM EDT
|Bid||20.05 x 4000|
|Ask||20.49 x 2000|
|Day's Range||20.22 - 20.88|
|52 Week Range||18.03 - 32.50|
|PE Ratio (TTM)||41.38|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx as a therapy for the treatment of individuals with advanced hepatocellular carcinoma (or HCC) who have previously undergone therapy. Exelixis’s sNDA was based on the results of its Phase 3 CELESTIAL trial. In October 2017, an independent data-monitoring committee recommended that Exelixis stop its CELESTIAL efficacy trial after a review of the second planned interim analysis, wherein Cabometyx demonstrated statistically significant and clinically meaningful progress in overall survival compared to the placebo in individuals who had already been treated for advanced HCC.
In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.
In 4Q17, Exelixis (EXEL) generated revenue of $115.9 million compared to $75.7 million in 4Q16, which reflected a ~55% rise on a year-over-year (or YoY) basis and a ~19% fall on a quarter-over-quarter basis. In 4Q17, Exelixis generated revenue of $95.7 million from net product sales and $24.4 million from collaborations. In 4Q17, Cabometyx primarily pushed this revenue growth.
Exelixis shares rebounded Tuesday from a 10-month low at Monday's close after regulators temporarily halted enrollment in a cancer study combining drugs from Exelixis and Roche.
A battle brewing in liver cancer will land Exelixis on top, an analyst said Wednesday after rival Eli Lilly posted strong topline results for its drug.
Exelixis (EXEL) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis' European partner, Ipsen, obtains positive opinion from the CHMP for the use of Cabometyx in the first-line treatment of advanced renal cell carcinoma.
Stocks are under fresh pressure after new Federal Reserve chairman Jerome Powell sounded a hawkish note in his first appearance before Congress this week. The odds of four quarter-point rate hikes is now rising fast, pressuring long-term Treasury yields higher, bringing back the headwind that pushed stocks into a correction earlier this month.
Exelixis and Clovis shares diverged Tuesday after each reported lackluster sales of their biggest cancer drugs in the fourth quarter.